












World Health Organization (WHO)-prequalified and Gavi, the Vaccine Alliance supported typhoid conjugate vaccines

Programmatic characteristics	Typbar TCV®	TYPHIBEV®
 MANUFACTURER	Bharat Biotech, India	Biological E, India
 VACCINE TYPE	Vi polysaccharide from <i>Salmonella</i> Typhi conjugated to tetanus toxoid carrier protein	Vi polysaccharide from <i>Citrobacter freundii</i> conjugated to CRM197 carrier protein*
 FORMULATION	Liquid: ready to use	
 ADMINISTRATION	Intramuscular injection	
 AGES	≥6 months to ≤65 years	≥6 months to ≤45 years
 NUMBER OF DOSES REQUIRED	1	
 WHO-PREQUALIFIED PRESENTATION(S) AVAILABLE WITH GAVI SUPPORT	5-dose vial	
 COLD CHAIN VOLUME	5-dose vial: 2.9 cm ³ /dose	
 SHELF LIFE	36 months at storage temperature: 2-8°C	24 months at storage temperature: 2-8°C
 VACCINE VIAL MONITOR (VVM) TYPE	Type 30	
 USE IN ROUTINE IMMUNIZATION PROGRAMS	India (Navi Mumbai only), Liberia, Pakistan, Samoa, Zimbabwe	Malawi, Nepal

August 2024

* Note: The Vi polysaccharide of *Citrobacter freundii* is structurally and immunologically the same as the Vi polysaccharide in *Salmonella* Typhi. (Rondini S et al. Evaluation of the immunogenicity and biological activity of the *Citrobacter freundii* Vi-CRM197 conjugate as a vaccine for *Salmonella enterica* serovar Typhi. *Clinical Vaccine Immunology*. 2011;18(3):460-468.)

Learn more and join the effort at www.takeontyphoid.org • #TakeOnTyphoid